The reported underlying lymphoproliferative disorders associated with acquired von Willebrand disease (AvWD) include benign monoclonal gammapathy, multiple myeloma, Waldenstr&ouml;m disease, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and hairy cell leukemia. The AvWD in patients with a monoclonal gammapathy and/or a lymphoproliferative disorder is featured by a prolonged bleeding time, normal platelet count, and a decreased or absent ristocetine-induced platelet aggregation in combination with a prolonged aPTT and normal PT due to low levels of factor VIII/von Willebrand factor (vWF) parameters in the absence of a factor VIII inhibitor in the Bethesda assay. In vitro and vivo experiments consistently showed that the anti-vWF autoanti-bodies in monoclonal gammapathies cause a rapid clearance of the factor VIII/vWF complex from the circulation after DDAVP and factor VIII/vWF concentrate infusion. Multimeric analysis of the vWF usually show a type 11-like AvWD due to the absence of large vWF multimers as the consequence of the rapid clearance of the anti-vWF-factor VIII/vWF complex from the circulation. There is a poor response to intravenous DDAVP and factor VIII/vWF concentrate infusion, but high dose intravenous gamma globulin (1 g/kg for 2 days) usually induces a transient correction of the factor VIII/vWF parameters for 1 to a few weeks.
Summary: The reported underlying lymphoproliferative disorders associated with acquired von Willebrand disease (AvWD) include benign monoclonal gammapathy, multiple myeloma, Waldenstr&ouml;m disease, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and hairy cell leukemia. The AvWD in patients with a monoclonal gammapathy and/or a lymphoproliferative disorder is featured by a prolonged bleeding time, normal platelet count, and a decreased or absent ristocetine-induced platelet aggregation in combination with a prolonged aPTT and normal PT due to low levels of factor VIII/von Willebrand factor (vWF) parameters in the absence of a factor VIII inhibitor in the Bethesda assay. In vitro and vivo experiments consistently showed that the anti-vWF autoanti-bodies in monoclonal gammapathies cause a rapid clearance of the factor VIII/vWF complex from the circulation after DDAVP and factor VIII/vWF concentrate infusion. Multimeric analysis of the vWF usually show a type 11-like AvWD due to the absence of large vWF multimers as the consequence of the rapid clearance of the anti-vWF-factor VIII/vWF complex from the circulation. There is a poor response to intravenous DDAVP and factor VIII/vWF concentrate infusion, but high dose intravenous gamma globulin (1 g/kg for 2 days) usually induces a transient correction of the factor VIII/vWF parameters for 1 to a few weeks. Key Words: Acquired von Willebrand syndrome&mdash;Monoclonal gammapathy&mdash;Intravenous gamma globulin. Acquired von Willebrand disease (AvWD) is a bleeding disorder similar to congenital von Willebrand disease in terms of clinical manifestations and laboratory findings being characterized by a prolonged bleeding time and low levels of factor VIII von Willebrand factor (factor VIII/vWF) complex, but without a family history of a congenital bleeding tendency and absence of abnormal bleeding after hemostatic challenges.
Other reports indicate that AvWD may occur in association with monoclonal gammapathies, multiple myeloma, and lymphoproliferative disorders. This article presents the clinical manifestations, factor VIII/vWF characteristics, coagulation, and platelet function studies in three cases of AvWD presenting as an acquired but persistent bleeding disorder in association with a benign monoclonal gammapathy. All three cases of AvWD associated with a benign monoclonal immunoglobulin re-sponded poorly to DDAVP and vWF concentrate replacement, but were successfully treated with high-dose intravenous gamma globulin. This new treatment option of AvWD in monoclonal gammapathies is discussed in view of recent data from the literature.
METHODS
Coagulation screening assays and platelet aggregation tests were performed routinely. Bleeding times were measured according to Ivy et al. (1) . The factor VIII coagulant activity (factor VIIIc) was assayed by means of the Automatic Coagulation Laboratory (ACL; Instrumental Laboratory, IJsselstein, The Netherlands) using factor VIII-deficient plasma (Ortho Diagnostics System, Beerse, Belgium) (2) . von Willebrand factor antigen was assayed by an enzyme-linked immunosorbent assay (ELISA), as described by Cejka (3) . Ristocetin cofactor activity of the vWF (vWF-RCF) was assayed with formaline-fixed platelets using a PAP4 model Aggregometer (Bio Data Corp., Hatboro, PA, USA) (4). The vWF binding activity to collagen (vWF-CBA) was measured according to the ELISA-based method of Brown and Bosak (5) with slight modifications as described (2) . The multimeric composition of vWF was analyzed by sodium (6) . Inhibitors against factor VIIIc were sought by the Bethesda method (7) . Inhibition of vWF-RCF and vWF-CBA were sought by incubating diluting volumes of patient plasma with one volume of pooled normal plasma.
PATIENTS

Case 1
A 36-year-old women presented with a recent and persistent history of bruises, ecchymoses, recurrent epistaxis, menorrhagias, secondary bleeding after laparotomy, and absent family history of a congenital bleeding tendency.
Case 2
A 30-year-old woman presented with a 2-year history of spontaneous bruises and ecchymoses, gum bleedings, and severe menorrhagias. Tonsillectomy in childhood and tooth extractions at adolescent age were uneventful.
Case 3
A 72-year-old man presented with bruises and prolonged bleeding after transurethral prostatectomy with no history of a familial or congenital bleeding disorder. Previous surgical challenges were uneventful.
RESULTS
Laboratory diagnosis
The results of platelet function tests and coagulation tests were similar in all three cases ( Table 1 ). The bleeding times were significantly prolonged. The ristocetininduced platelet aggregation (RIPA) was absent in two cases on repeated occasions and decreased in one case. The prolongation of the activated partial thromboplastin time (aPTT) was in accordance with the low levels of factor VIII coagulant activity. Inhibitors against factor VIIIIc in the Bethesda assay were absent. Low levels for vWF-antigen (Ag) and low levels for vWF-RCF and vWF-CBA can explain the prolongation of the bleeding times because platelet aggregation curves induced by collagen, adenosine diphosphate (ADP), and adrenaline were normal. Incubation experiments of patients' plasma and normal plasma in all three cases showed no inhibition of vWF-Ag, vWF-RCF, and vWF-CBA. As compared to the normal control, plasma high-molecular weight multimers of vWF were absent in all three cases (Fig. 1 ).
Treatment
Factor VIIIlvWF concentrate replacement The preventive DDAVP administration was contraindicated in case 1 because of hypertension. A total abdominal hysterectomy was planned and bleeding was intended to be prevented by vWF replacement therapy with Hemate-P (Boehringer, Marburg, Germany) under careful laboratory monitoring (Fig. 2 ). Factor VIII vWF concentrate Hemate-P 4,000 U four times a day resulted in normal top levels of vWF-RCF and vWF-CBA and correction of the bleeding times followed by a rapid decline of vWF-CBA to <0.05 )JL/mL and vWF-RCF to about 0.20 to 0.30 pL/mL and prolongation of the bleeding times within 6 hours just before the next dose of factor VIII/vWF concentrate was given (Fig. 2 ). However, severe bleeding from surgical wounds complicated by hypovolemic shock occurred on postoperative day 6.
Control of bleeding and hemostatic levels of vWF-CBA and vWF-RCF could be obtained by repeated transfusion of 4,000 R Hemate-P 8 to 12 times a day (Fig. 2 ). Highdose ( g/kg for 2 days) gamma globulin (Central Laboratory for Blood Transfusion Services, Amsterdam, The Netherlands) on postoperative day 10 and subsequent discontinuation of Hemate-P substitution was followed FIG. 1. Absence of large von Willebrand factor (vWF) multimers in case 1 with acquired von Willebrand disease (AvWD) associated with a monoclonal gammapathy.
as expected (8) by complete normal levels of all vWF parameters for 2 to 3 weeks followed by a slow decline of the vWF parameters in weeks 3 and 4 to very low levels (9) . the circulation of all vWF parameters with half-life times <2 hours (Fig. 3 ).
DDAVP DDAVP infusion (0.4 J.1g/kg) in cases 2 and 3 induced a short-term partial increase of the vWF parameters immediately after the infusion and no correction of the bleeding times (Fig. 3 ).
High-dose intravenous gamma globulin
Case 2 received an experimental treatment with highdose gammaglobulin 1 g/kg for 2 days, which was followed by correction of the vWF parameters and bleeding times for about 1 week to 10 days (Fig. 4 ). Case 2 received a second treatment of high-dose gamma globulin 1 g/kg for 2 days. Subsequent infusion of a relatively low dose of 2,000 U of Hemate-P resulted in complete correction of all vWF parameters and bleeding times followed by normal half-life times >18 hours for vWF-RCF and vWF-CBA ( Fig. 5 ). 
REVIEW OF THE LITERATURE
Clinical manifestations
The underlying lymphoproliferative disorders in the first 65 reported cases on AvWD in the literature (14) are summarized in Table 2 . The underlying disorders associated with AvWD in 65 cases were benign monoclonal gammapathy in 30, multiple myeloma in 12, Walden-str6m disease in 5, chronic lymphocytic leukemia in 7, non-Hodgkin lymphoma in 8, and hairy cell leukemia in 2. The main clinical manifestations include frequent and recurrent epistaxis, easy bruising, menorrhagias, and recurrent blood loss from the gastrointestinal tract combined with a negative family history of a congenital bleeding disorder and no history of excessive bleeding after previous hemostatic challenges. The ages at which AvWD occurred ranged from 30 to 85 years, equally divided over both sexes.
Laboratory findings
The pertinent findings in the reviewed cases of AvWD associated with a monoclonal gammapathy and/or a lymphoproliferative disorder are (2, (8) (9) (10) (11) (12) (13) (14) ; 
2.
A decreased or absent RIPA in nearly all cases. 3. A prolonged aPTT and normal prothrombin time (PT) with correction of the aPTT after mixture of patient and normal plasma. 4. Low levels of factor VIIIc, vWF-Ag, vWF-RCF, and vWF-CBA. 5. Absence of a factor VIII inhibitor in the Bethesda assay. 6. Inhibition of vWF-RCF or vWF-CBA in a mixture of patient plasma and normal control plasma was observed in a minority of the cases. 7. On multimeric analysis of the vWF a type II-like AvWD multimeric pattern (absence of large vWF multimers) was seen in the majority of the cases. 8 . Poor response to intravenous DDAVP.
9. Rapid clearance of all vWF parameters after infusion of factor VIII/vWF concentrate.
10. Transient correction of vWF parameters for 1 to a few weeks after high-dose intravenous gamma globulin.
DISCUSSION
Most anti-vWF antibodies in AvWD associated monoclonal gammapathy and/or lymphoid disorders (Table 2) belong to the IgG class, although occasionally IgM or IgA is reported, even in the presence of an IgG-related paraprotein (2) . In about 20% of the autoantibodies against vWF in AvWD associated with a monoclonal gammapathy or lymphoid disorders, an inhibitor against vWF may be demonstrable in vitro (14) . Anti-vWF autoantibodies may inhibit active sites on vWF (neutralizing antibodies) by reacting with the active site itself or diminishing the function of a part of vWF as a consequence of steric hindrance. Anti-vWF antibodies may also be directed against nonfunctional sites on vWF (non-neutralizing antibodies). In vitro, the anti-vWF antibodies can be demonstrated only after isolation of particular immune complexes or immunoglobulin fractions or by competitive ELISAs (11) . In vivo experiments have consistently shown that neutralizing and nonneutralizing anti-vWF antibodies cause a rapid clearance of the vWF-factor VIII complex from the circulation, as could be demonstrated by the shortened half-life times (12, 13) . Our data could confirm that infusion of factor VIII/vWF concentrate (Hemate-P) or DDAVP in cases of AvWD associated with a monoclonal gammapathy resulted in low recovery and rapid clearance of the large vWF multimers and the factor VIII/vWF complex, reflecting the presence of an autoantibody against the vWF-factor VIII complex (Fig. 2 and 3 ) (2, 8, 9) . A functional inhibitor (neutralizing autoantibody) selectively directed against the vWF as demonstrated in vitro in only a minority of the cases of AvWD associated with a monoclonal gammapathy (2, 8) , cannot explain the rapid clearance of the factor VIII/vWF complex. Therefore, the binding of the autoantibody to the large vWF multimers of circulating factor VIII/vWF is probably responsible for the rapid clearance of the antigen/antibody complex from the circulation, which results in low circulating levels of factor VIII and vWF. The large vWF multimers are known to possess the vWF-RCF and the vWF-CBA.
Defective production, processing or release of vWF from endothelial cells, is unlikely by the demonstration of a significant rise of the factor VIII/vWF complex parameters after DDAVP infusion (2, 8, 9, 14) .
In the absence of a detectable inhibitor in our three cases of AvWD associated with benign monoclonal gammapathy, the IgG monoclonal immunoglobulins are thought to bind nonspecifically to the vWF protein or were postulated to interact specifically to the large vWF multimers without disturbing its functional or immunologic properties, but resulting in rapid clearance of the antibody-antigen complexes from the circulation. Previously, we reviewed ten additional cases of AvWD associated with a monoclonal gammapathy in whom highdose intravenous gamma globulin was successful (9) . Gamma globulin therapy was administered at a dose ranging from 0.4 to 1.0 g/kg body weight for 2 to 8 days. Peak values for vWF parameters compared to those found in Fig. 4 were observed after 1 to 2 weeks. Gamma globulin usually improved the coagulation defect for about 2 to 3 weeks. The interesting finding is that the clearance of the factor VIII/vWF complex in AvWD associated with a monoclonal gammapathy is delayed immediately after treatment of high-dose intravenous immunoglobulin (case 2, Fig. 5 ) (10). This offers the opportunity to treat severe or life-threatening bleeding episodes by high-dose intravenous gamma globulin immediately followed by substitution of factor VIII/vWF concentrate in an attempt to control the bleeding by obtaining hemostatic levels of vWF within a short period.
